Drug Metabolism Reviews

Papers
(The TQCC of Drug Metabolism Reviews is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
CYP24A1: the pivotal regulator of vitamin D homeostasis, pathophysiology in metabolic and genetic disease, and emerging target for precision medicine53
Drug transporters in drug disposition – the year 2022 in review48
Mechanisms of intestinal pharmacokinetic natural product-drug interactions41
Phase II metabolism in xenobiotic biotransformation: general mechanisms and the underestimated role of microbial systems36
An in-depth review of PPARγ modulators as anti-diabetes therapeutics23
Differential modulation of cytochrome P450 enzymes by arsenicals in non-human experimental models22
Enantioselectivity in some physiological and pathophysiological roles of hydroxyeicosatetraenoic acids20
New strategy for rational use of antihypertensive drugs in clinical practice in high-altitude hypoxic environments18
A critical review of analytical tools for the detection of spironolactone and its metabolites16
Cytochrome P450-mediated carbon-carbon bond formation in drug metabolism15
Assessing and mitigating pH-mediated DDI risks in drug development – formulation approaches and clinical considerations15
Multimolecular interactions from Chinese medicines activate nuclear receptor conformational changes: a potential strategy for anti-inflammatory therapy14
Redox enzyme networks shaping cancer drug metabolism and therapeutic resistance13
Biopolymers as promising vehicles for drug delivery to the brain13
Transporter-mediated drug-drug interactions: regulatory guidelines, in vitro and in vivo methodologies and translation, special population12
Drug transporters in drug disposition – highlights from the year 202412
Genetic determinants of paclitaxel-induced peripheral neuropathy: a review of current literature12
Clinical pharmacokinetics of nebivolol: a systematic review11
Metabolism of new drug modalities research advances – 2024 year in review11
Scaling factors to inform in vitro - in vivo extrapolation from preclinical and livestock animals: state o10
Metabolic activation of tyrosine kinase inhibitors: recent advance and further clinical practice10
A transcriptional regulatory network of HNF4α and HNF1α involved in human diseases and drug metabolism10
Pharmacomicrobiomics in precision pharmacotherapy: bidirectional microbial-drug interactions as a key determinant of therapeutic response9
Biotransformation research advances—2025 year in review9
Molecular insights into doxorubicin-induced cardiotoxicity and phytochemical-based cardioprotection: challenges and future strategies8
Effects of intestinal flora on pharmacokinetics and pharmacodynamics of drugs8
Favipiravir, remdesivir, and lopinavir: metabolites, degradation products and their analytical methods8
0.055546998977661